Wedbush Reconfirms a Outperform Rating on Epizyme (EPZM) and $20 Target; Vulcan Value Partners Trimmed United Technologies (UTX) Holding By $6.10 Million

April 24, 2018 - By William Brooks

Epizyme, Inc. (NASDAQ:EPZM) Logo

In a research report issued to clients on Tuesday morning, Epizyme (NASDAQ:EPZM) stock Outperform was restate by Analysts at Wedbush. They currently have a $20 target price per share on the stock. Wedbush’s target price per share would indicate a potential upside of 30.72% from the company’s stock close price.

Vulcan Value Partners Llc decreased United Technologies Corp (UTX) stake by 5.28% reported in 2017Q4 SEC filing. Vulcan Value Partners Llc sold 48,040 shares as United Technologies Corp (UTX)’s stock declined 1.53%. The Vulcan Value Partners Llc holds 862,037 shares with $109.97 million value, down from 910,077 last quarter. United Technologies Corp now has $98.78 billion valuation. The stock increased 0.31% or $0.38 during the last trading session, reaching $123.46. About 3.28 million shares traded. United Technologies Corporation (NYSE:UTX) has risen 12.03% since April 24, 2017 and is uptrending. It has outperformed by 0.48% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.06 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

Since February 5, 2018, it had 0 buys, and 1 insider sale for $1.20 million activity. Ros Matthew sold $1.20M worth of stock.

Investors sentiment decreased to 1.21 in 2017 Q4. Its down 0.25, from 1.46 in 2017Q3. It turned negative, as 15 investors sold Epizyme, Inc. shares while 24 reduced holdings. 12 funds opened positions while 35 raised stakes. 56.93 million shares or 1.91% less from 58.04 million shares in 2017Q3 were reported. 47,352 are held by Bancorp Of America De. Nea Ltd owns 6.46 million shares or 3.36% of their US portfolio. Landscape Cap Mngmt Ltd Liability Company owns 0.06% invested in Epizyme, Inc. (NASDAQ:EPZM) for 51,077 shares. Meeder Asset Management Inc stated it has 0% in Epizyme, Inc. (NASDAQ:EPZM). Rhenman & Ptnrs Asset Ab holds 217,591 shares or 0.37% of its portfolio. Redmile Grp Inc Ltd Limited Liability Company has invested 1.05% in Epizyme, Inc. (NASDAQ:EPZM). Qs Investors Lc accumulated 0.01% or 87,802 shares. Royal Commercial Bank Of Canada holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 1,705 shares. Great West Life Assurance Company Can has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Foresite Capital Ii Ltd reported 1.56 million shares or 6.83% of all its holdings. Citadel Advisors Ltd Company has 552,089 shares. Proshare Advsrs Ltd holds 0% in Epizyme, Inc. (NASDAQ:EPZM) or 44,597 shares. Alliancebernstein L P holds 38,200 shares. Geode Cap Mgmt Ltd Limited Liability Company invested 0% in Epizyme, Inc. (NASDAQ:EPZM). State Street owns 2.01M shares or 0% of their US portfolio.

The stock decreased 3.47% or $0.55 during the last trading session, reaching $15.3. About 190,284 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 1.14% since April 24, 2017 and is uptrending. It has underperformed by 10.41% the S&P500.

Among 13 analysts covering Epizyme (NASDAQ:EPZM), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme has $42 highest and $17 lowest target. $23.83’s average target is 55.75% above currents $15.3 stock price. Epizyme had 33 analyst reports since August 6, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of EPZM in report on Thursday, November 2 with “Buy” rating. Mizuho maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Thursday, August 6. Mizuho has “Buy” rating and $26 target. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. Leerink Swann maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Wednesday, March 14. Leerink Swann has “Outperform” rating and $24 target. RBC Capital Markets downgraded the shares of EPZM in report on Thursday, November 2 to “Sector Perform” rating. H.C. Wainwright maintained it with “Buy” rating and $2500 target in Wednesday, June 7 report. Oppenheimer maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Monday, July 24. Oppenheimer has “Buy” rating and $2600 target. The stock has “Buy” rating by Leerink Swann on Thursday, June 15. Jefferies initiated it with “Buy” rating and $25.0 target in Wednesday, January 24 report. The firm earned “Buy” rating on Wednesday, June 7 by Cowen & Co.

Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on May, 14. They expect $-0.54 earnings per share, up 3.57% or $0.02 from last year’s $-0.56 per share. After $-0.52 actual earnings per share reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts 3.85% negative EPS growth.

Investors sentiment decreased to 0.92 in Q4 2017. Its down 0.13, from 1.05 in 2017Q3. It fall, as 58 investors sold UTX shares while 554 reduced holdings. 121 funds opened positions while 441 raised stakes. 624.06 million shares or 0.48% more from 621.08 million shares in 2017Q3 were reported. Lau Assoc Limited Liability Corporation has invested 1.25% in United Technologies Corporation (NYSE:UTX). Jolley Asset Ltd Liability Corp stated it has 0.07% of its portfolio in United Technologies Corporation (NYSE:UTX). The Connecticut-based Gillespie Robinson & Grimm Incorporated has invested 0.05% in United Technologies Corporation (NYSE:UTX). Valicenti Advisory Ser Inc stated it has 1.48% of its portfolio in United Technologies Corporation (NYSE:UTX). South Dakota Invest Council accumulated 0.14% or 49,300 shares. Blue Chip Prtnrs reported 3,185 shares. Sterling Ltd Liability invested in 90,747 shares or 0.1% of the stock. Hightower Advsrs Limited Liability Corporation accumulated 234,700 shares. Newfocus Fincl Gru Ltd Liability Corp invested 1.16% of its portfolio in United Technologies Corporation (NYSE:UTX). Koch Industries owns 2,592 shares or 0.05% of their US portfolio. Murphy Mngmt Inc holds 1.48% or 84,746 shares in its portfolio. Moreover, Toronto Dominion Bank & Trust has 0.13% invested in United Technologies Corporation (NYSE:UTX). Wesbanco Bank Inc reported 124,834 shares. Rdl has 9,151 shares. Capwealth Ltd Limited Liability Company accumulated 57,559 shares.

Among 21 analysts covering United Technologies Corporation (NYSE:UTX), 12 have Buy rating, 0 Sell and 9 Hold. Therefore 57% are positive. United Technologies Corporation had 84 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Monday, February 26. The stock of United Technologies Corporation (NYSE:UTX) has “Outperform” rating given on Thursday, July 23 by Cowen & Co. The firm has “Buy” rating by Jefferies given on Tuesday, October 3. Robert W. Baird upgraded United Technologies Corporation (NYSE:UTX) on Friday, January 5 to “Outperform” rating. RBC Capital Markets maintained United Technologies Corporation (NYSE:UTX) on Thursday, January 12 with “Sector Perform” rating. RBC Capital Markets maintained it with “Hold” rating and $12500 target in Friday, June 2 report. The stock has “Buy” rating by Citigroup on Thursday, September 10. Goldman Sachs upgraded United Technologies Corporation (NYSE:UTX) on Monday, January 8 to “Buy” rating. The stock of United Technologies Corporation (NYSE:UTX) earned “Hold” rating by Deutsche Bank on Monday, September 21. CItigroup downgraded the shares of UTX in report on Monday, October 10 to “Neutral” rating.

Since December 13, 2017, it had 0 insider buys, and 5 insider sales for $1.06 million activity. Shares for $546,600 were sold by Amato Elizabeth B on Friday, December 15. Another trade for 2,032 shares valued at $274,217 was sold by Bailey Robert J..

United Technologies Corporation (NYSE:UTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 William Brooks

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: